Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0034063 (
pulmonary edema
)
10,665
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Simvastatin belongs to a class of lipid-lowering drugs which completely inhibit 3-hydroxy-3-methylglutaryl co-enzyme A (HMG CoA) reductase. The commonest adverse effects of therapy with simvastatin
HMG CoA reductase
inhibitors are gastro-intestinal disturbance, myositis and myopathy. Rhabdomyolysis leading to renal failure has been reported, but it appears to be very rare, except in patients also receiving cyclosporin, nicotinic acid or gemfibrozil. Here we report the case of an elderly lady who was known to have chronic renal failure, but who developed rhabdomyolysis following simvastatin therapy. Her symptoms of muscle pain, fatigue, myoglobulinuria, oliguria and
pulmonary oedema
appeared 48 h after the first dose of simvastatin. Simvastatin was immediately stopped, and the patient was dialysed for 1 week. Her renal function improved and came back. We suggest that extreme care should be exercised in prescribing this drug, particularly for the elderly with renal impairment.
...
PMID:Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure. 1127 41
Acute respiratory distress syndrome is a frequently encountered condition in the intensive care units, with high mortality rates despite cumulating knowledge on its pathogenesis. It is important that cardiac
pulmonary edema
should be ruled out for diagnosis. Different mechanical ventilation strategies, as well as agents for the control of inflammation are being tested. Currently, low tidal volume ventilation with high PEEP and plateau pressures below 30 cmH(2)O is the only intervention that has been shown to improve survival significantly. Low dose steroids, nitric oxide inhalation, surfactant, antioxidants, Beta(2) adrenergic agents,
HMG-CoA reductase
inhibitors are promising agents. Fluid restriction and immunonutrition should be considered when these patients are being cared for.
...
PMID:[Current strategies for the diagnosis and treatment of acute respiratory distress syndrome]. 1971 18